Your session is about to expire
← Back to Search
Part A; Cohort 3 for Alzheimer's Disease
Study Summary
This trial is testing a new drug to see if it is safe and effective in humans.
- Alzheimer's Disease
- Epilepsy
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Frequently Asked Questions
How many people does the research team plan to recruit for this trial?
"Affirmative. The data on clinicaltrials.gov indicates that the study, which was first made visible to the public on October 20th 2022, is presently recruiting candidates for participation. 48 participants need to be gathered from a single site."
Would I meet the prerequisites for joining this medical experiment?
"This trial has room for 48 people living with epilepsy and aged between 19 to 55 years old. Eligibility criteria includes a Body Mass Index of 18-32 kg/m2, negative pregnancy test results in females at screening and upon admission, abstinence or contraceptive use during the study duration (90 days after the last dose) plus 90 days post treatment, swallowing pills capability, as well as a minimum body weight of 50kg for males and 45kg for females."
Does the age requirement of this research extend to those under 25 years of age?
"To meet the criteria of this trial, potential participants must be between 19 and 55 years old. At present, there are 126 trials available for minors while 696 are tailored to those over 65 years old."
What degree of hazard is associated with Part A; Cohort 3?
"There is scant data to support the safety and efficacy of Part A; Cohort 3, so it earned a score of 1."
What objectives is this investigation attempting to accomplish?
"The primary goal of this study, which will occur over a span of up to 7 days, is to assess the number of participants with abnormal vital signs. Additionally, researchers are interested in 3 pharmacokinetic variables: apparent volume of distribution during terminal elimination phase (VzF), area under plasma concentration-time curve from zero to last quantifiable (AUClast) and area under plasma concentration-time curve extrapolated to infinity (AUCinf)."
Are there still openings available for enrollees in this research study?
"Affirmative. Clinicaltrials.gov contains data that demonstrates this clinical trial is actively recruiting patients; the initial posting was on October 20th, 2022 and it has been updated since then. The study seeks to enrol 48 individuals at a single site."
Share this study with friends
Copy Link
Messenger